Category: Interpretational.com

Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

BOTHELL, Wash. & TOKYO–(BUSINESS WIRE[1])–Seattle Genetics, Inc[2]. (Nasdaq:SGEN) and Astellas Pharma Inc.[3] (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy. The results were reviewed by an independent Data Monitoring Committee following a planned interim analysis. The global EV-301...

READ MORE Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

SAN DIEGO–(BUSINESS WIRE[1])–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN Kidney Week 2019 in Washington, D.C. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. The trial achieved the...

READ MORE Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

The association between exaggeration in health related science news and academic press releases: retrospective observational study

Petroc Sumner, professor12, Solveiga Vivian-Griffiths, research assistant12, Jacky Boivin, professor2, Andy Williams, lecturer3, Christos A Venetis, senior lecturer4, Aimée Davies, research assistant2, Jack Ogden, research assistant2, Leanne Whelan, research assistant2, Bethan Hughes, research assistant2, Bethan Dalton, research assistant2, Fred Boy, senior lecturer5, Christopher D Chambers, professor12 1Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff CF10 3AT,...

READ MORE The association between exaggeration in health related science news and academic press releases: retrospective observational study

Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

— Final Day 29 Data Show Superior Efficacy of Veklury Compared with Placebo in Hospitalized Patients Receiving Standard of Care — — Overall, Treatment with Veklury Resulted in Five Days Faster Recovery and Reduced Disease Progression Compared with Placebo — — Veklury Reduced Mortality by 70 Percent at Day 29 in Patients on Low-Flow Oxygen at Baseline in Post-Hoc Analysis...

READ MORE Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

Generated by Feedzy